The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Therapeutic effect of Edaravone on the patients with acute cerebral infarction
Author(s): 
Pages: 20-22
Year: Issue:  5
Journal: WORLD HEALTH DIGEST·MEDICAL MONTHLY

Keyword:  依达拉奉急性脑梗死疗效;
Abstract: 目的疗组(40例)及安慰荆对照组(42例).治疗组给予依达拉奉注射液30mg静脉滴注评价依达拉奉注射液治疗急性脑梗死(ACI)的临床疗效和安全性.方法采用随机对照试验,选择发病24h内的ACI患者82例.随机分为依达拉奉治,每日2次,共14d,同时给予阿司匹林、丹参作为基础治疗;对照组用等量安慰剂替代依达拉奉,余均同治疗组.治疗前后定期对患者进行欧洲卒中评分(ESS)、日常生活活动能力(ADL)评定和常规检查,以治疗第21dESS增分率和第90d ADL增分率作为主要疗效判断标准.结果 21d后治疗组、对照组ESS增分率分别为(60.9±26.7)%、(36.1±23.7)%,两组相比差异有极显著性(P<0.01);90d后治疗组、对照组ADL增分率分别为(71.8±27.3)%、(45.4±27.8)%,两组相比差异有极显著性(P<0.01);治疗组无明显不良反应.结论依达拉奉治疗ACI是安全有效的.
Related Articles
No related articles found